Edwards Lifesciences (EW) Non-Current Debt (2016 - 2025)
Edwards Lifesciences has reported Non-Current Debt over the past 17 years, most recently at $598.3 million for Q4 2025.
- Quarterly results put Non-Current Debt at $598.3 million for Q4 2025, changed 0.1% from a year ago — trailing twelve months through Dec 2025 was $598.3 million (changed 0.1% YoY), and the annual figure for FY2025 was $598.3 million, changed 0.1%.
- Non-Current Debt for Q4 2025 was $598.3 million at Edwards Lifesciences, roughly flat from $598.2 million in the prior quarter.
- Over the last five years, Non-Current Debt for EW hit a ceiling of $598.3 million in Q4 2025 and a floor of $595.2 million in Q1 2021.
- Median Non-Current Debt over the past 5 years was $596.8 million (2023), compared with a mean of $596.8 million.
- Biggest five-year swings in Non-Current Debt: increased 0.12% in 2021 and later increased 0.1% in 2025.
- Edwards Lifesciences' Non-Current Debt stood at $595.7 million in 2021, then grew by 0.1% to $596.3 million in 2022, then rose by 0.12% to $597.0 million in 2023, then increased by 0.12% to $597.7 million in 2024, then rose by 0.1% to $598.3 million in 2025.
- The last three reported values for Non-Current Debt were $598.3 million (Q4 2025), $598.2 million (Q3 2025), and $598.0 million (Q2 2025) per Business Quant data.